OBJECTIVE: To determine if cellular interleukin-6 production predicts response to tyrosine kinase inhibitors (TKIs). As clinical experience using TKIs in patients with castration-resistant prostate cancer (CRPC) matures, Phase II trials show a heterogeneous response to sunitinib in CRPC patients. Change in serum prostate-specific antigen (PSA) level has proven unreliable for prediction of CRPC response to TKIs. Interleukin-6 (IL-6), a critical mediator of prostate cancer pathogenesis, has been shown to rise in patients with disease progression. As such, we investigated whether cellular IL-6 production can predict TKI response in both in vitro and in vivo models. METHODS: IL-6 mRNA levels and protein expression were examined by reverse transcriptase-polymerase chain reaction and enzyme-linked immunosorbent assay, respectively. Apoptosis was examined using the terminal dUTP nick-end labeling assay. For in vivo studies, a CRPC xenograft model in C.B17/Icr-scid mice was used. RESULTS: PC-3 and DU-145 CRPC cell lines exhibited a heterogeneous response to sunitinib and pazopanib. Dose-dependent reduction of IL-6 was observed in TKI-sensitive DU-145 cells. In contrast, the TKI-resistant PC-3 cells failed to suppress IL-6 secretion. Instead, in the presence of tumor necrosis factor-alpha, IL-6 rose significantly upon administration of TKIs. Findings of in vitro experiments were confirmed in an in vivo mouse model of CRPC. CONCLUSION: Sensitivity of CRPC cells to TKIs is heterogeneous. These findings are consistent with results of recently published Phase II clinical trials using sunitinib in patients with CRPC. A substantial rise in IL-6 occurs both in vitro and in vivo in the presence of TKIs in resistant PC-3 cells but not in TKI-sensitive DU-145 cells. These findings suggest that IL-6 may represent a biomarker for TKI resistance in patients with CRPC.
OBJECTIVE: To determine if cellular interleukin-6 production predicts response to tyrosine kinase inhibitors (TKIs). As clinical experience using TKIs in patients with castration-resistant prostate cancer (CRPC) matures, Phase II trials show a heterogeneous response to sunitinib in CRPC patients. Change in serum prostate-specific antigen (PSA) level has proven unreliable for prediction of CRPC response to TKIs. Interleukin-6 (IL-6), a critical mediator of prostate cancer pathogenesis, has been shown to rise in patients with disease progression. As such, we investigated whether cellular IL-6 production can predict TKI response in both in vitro and in vivo models. METHODS:IL-6 mRNA levels and protein expression were examined by reverse transcriptase-polymerase chain reaction and enzyme-linked immunosorbent assay, respectively. Apoptosis was examined using the terminal dUTP nick-end labeling assay. For in vivo studies, a CRPC xenograft model in C.B17/Icr-scid mice was used. RESULTS:PC-3 and DU-145 CRPC cell lines exhibited a heterogeneous response to sunitinib and pazopanib. Dose-dependent reduction of IL-6 was observed in TKI-sensitive DU-145 cells. In contrast, the TKI-resistant PC-3 cells failed to suppress IL-6 secretion. Instead, in the presence of tumor necrosis factor-alpha, IL-6 rose significantly upon administration of TKIs. Findings of in vitro experiments were confirmed in an in vivo mouse model of CRPC. CONCLUSION: Sensitivity of CRPC cells to TKIs is heterogeneous. These findings are consistent with results of recently published Phase II clinical trials using sunitinib in patients with CRPC. A substantial rise in IL-6 occurs both in vitro and in vivo in the presence of TKIs in resistant PC-3 cells but not in TKI-sensitive DU-145 cells. These findings suggest that IL-6 may represent a biomarker for TKI resistance in patients with CRPC.
Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: G Sonpavde; P O Periman; D Bernold; D Weckstein; M T Fleming; M D Galsky; W R Berry; F Zhan; K A Boehm; L Asmar; T E Hutson Journal: Ann Oncol Date: 2009-07-24 Impact factor: 32.976
Authors: Andrew X Zhu; Dushyant V Sahani; Dan G Duda; Emmanuelle di Tomaso; Marek Ancukiewicz; Onofrio A Catalano; Vivek Sindhwani; Lawrence S Blaszkowsky; Sam S Yoon; Johanna Lahdenranta; Pankaj Bhargava; Jeffrey Meyerhardt; Jeffrey W Clark; Eunice L Kwak; Aram F Hezel; Rebecca Miksad; Thomas A Abrams; Peter C Enzinger; Charles S Fuchs; David P Ryan; Rakesh K Jain Journal: J Clin Oncol Date: 2009-05-26 Impact factor: 44.544
Authors: J L Perez-Gracia; C Prior; F Guillén-Grima; V Segura; A Gonzalez; A Panizo; I Melero; E Grande-Pulido; A Gurpide; I Gil-Bazo; A Calvo Journal: Br J Cancer Date: 2009-11-10 Impact factor: 7.640
Authors: Bilal Bin Hafeez; Joseph W Fischer; Ashok Singh; Weixiong Zhong; Ala Mustafa; Louise Meske; Mohammad Ozair Sheikhani; Ajit Kumar Verma Journal: Cancer Prev Res (Phila) Date: 2015-01-27
Authors: Michalis Mastri; Spencer Rosario; Amanda Tracz; Robin E Frink; Rolf A Brekken; John M L Ebos Journal: Curr Drug Targets Date: 2016 Impact factor: 3.465
Authors: Peter Makhov; Sei Naito; Miki Haifler; Alexander Kutikov; Yanis Boumber; Robert G Uzzo; Vladimir M Kolenko Journal: Cell Death Dis Date: 2018-03-07 Impact factor: 8.469
Authors: Roberta M Moretti; Marina Montagnani Marelli; Deanne M Taylor; Paolo G V Martini; Monica Marzagalli; Patrizia Limonta Journal: PLoS One Date: 2014-04-10 Impact factor: 3.240